Affiliations
- State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, People's Republic of China.
- Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun, People's Republic of China.
- Academicians Workstation of Jilin Province, Changchun University of Chinese Medicine, Changchun, People's Republic of China.
- Research Unit of Discovery and Tracing of Natural Focus Diseases, Chinese Academy of Medical Sciences, Beijing, People's Republic of China.
PMID: 36947428 PMCID: PMC10071941 DOI: 10.1080/22221751.2023.2192815
Abstract
Background: The re-emerging mpox virus (MPXV), a member of the Orthopoxvirus genus along with variola and vaccinia viruses, led to a public health emergency in 2022. Inspired by the success of COVID-19 mRNA vaccines, this study developed a multicomponent mRNA vaccine platform to target MPXV.
Methods: Multiple MPXV antigen-encoding mRNA vaccines were constructed, and their immunogenicity and protection efficacy were evaluated in mouse models.
Results: The penta- and tetra-component mRNA vaccines (AR-MPXV5 and AR-MPXV4a) elicited strong antibody responses and protected mice against vaccinia virus challenge.
Conclusion: These mRNA vaccines show promise for development as multicomponent immunizations against MPXV.
Keywords
Mpox virus; mRNA vaccine; mouse model; multicomponent; protective antigen.
